Posts Tagged ‘Canary Challenge’
February 4, 2014
In honor of World Cancer Day, we are officially opening registration for the Canary Challenge 2014. Register for the ride now for $25 until March 31.
World Cancer Day is a chance to raise our collective voices in the name of improving general knowledge around cancer and dismissing misconceptions about the disease. For Canary, we’re emphasizing the need for more cancer early detection research, awareness, and advocacy. A great way to get involved is by participating in the Canary Challenge 2014.
This amazing one-day cycling event is about to get bigger and better than ever. The event will be hosted at HP’s campus in Palo Alto on Hanover St. We’re aiming high this year with a goal of raising $1.5 million, recruiting 150 teams and over 1,500 riders. This year’s ride will benefit the Canary Center at Stanford, supporting the researchers, scientists and doctors who are dedicated to cancer early detection. Register now and be part of the pioneering edge of cancer early detection research!
January 29, 2014
The beginning of the year presents a cue to reflect on the successes of the previous year, and look forward to goals for the coming months. We’re delighted to announce progress with our research that has tremendous implications for future innovations, as well as our ambitions for the Canary Challenge 2014.
New technologies always evoke excitement and anticipation. Here at Canary, if a scientist wants to use a new technology to advance or improve the ways we detect cancer tumors early, we are all for it. Enhanced ultrasound using microbubble technology is one of these technologies.
This technology will change the way doctors view tumors. Microbubbles are miniature gas bubbles, mostly containing oxygen or air, which can be uniformly suspended in a liquid such as blood. Due to their size, they can pass through even the smallest of blood vessels and therefore are commonly used together with medical ultrasound imaging. As effective vehicles for highlighting blood in ultrasound images, Canary scientists use microbubbles as a contrast agent to view cancer tumors. Our clinical trials in Rome with women who have ovarian cancer have produced great results. Here in the US, we anticipate replicating microbubble technology for applications with breast cancer, prostate and pancreatic cancer.
We also value and actively seek out key partnerships, whether academic or industry. Soon we’ll announce a partnership with Genomic Health Inc. in the area of prostate cancer. We’re in talks with MD Anderson in Houston to help with coordinating a national multi-institutional lung cancer study.
We have great plans for our largest fundraising event, the Canary Challenge, which is about to get bigger and better than ever. Mark your calendar now for September 27, 2014. Register now for $25 until March 31. The event will be hosted at HP’s campus in Palo Alto on Hanover St. We’re aiming high this year with a goal of raising $1.5 million, recruiting 150 teams and over 1,500 riders. This year’s ride will benefit the Canary Center at Stanford, supporting the researchers, scientists and doctors who are dedicated to cancer early detection. Come be a part of an amazing one-day cycling event!
We’re pleased to announce that we will again be partnering with women’s pro cycling team extraordinaire, the Vanderkittens, who will host monthly training rides for Canary Challenge riders. Hani Juha, a cyclist and great coach, of Menlo Bike Club will also offer weekly training rides, an annual training program, as well as monthly clinics. We invite anyone and everyone in the Canary community to take advantage of these tailored experiences to brush up on their skills in time for the event.
What are your hopes and dreams for cancer early detection research at Canary Foundation? Let us know in the comments below!
December 16, 2013
Save the date to register for the Canary Challenge 2014- registration opens on January 4 in the New Year!
December 4, 2013
Canary Foundation’s progress continues to be on a rapid path. Through prestigious partnerships, research, and clinical trials with quantifiable results, Canary Foundation is funding early detection research that will save lives and permanently change the landscape of cancer diagnostics. People like you have made this progress possible.
In 2013, our partnership with Stanford University expanded and we moved into our new state-of-the-art Canary Center at Stanford to continue our work realizing early detection solutions.
We are pleased to share a new video featuring our high points. We thought this was a great way to reflect on key ideas Canary was founded upon that have become reality. We invite you to view our 5-minute Canary Foundation video!
When you and your family make giving decisions this holiday, we ask that make cancer early detection a priority. Please give generously.
November 14, 2013
About one man in six will be diagnosed with prostate cancer in his lifetime. Most men diagnosed with prostate cancer will not die from it. With screening, we’re doing better at identifying prostate cancer early. But now, the clinical question is: with a prostate cancer diagnosis, do we treat, or is treatment not necessary?
Treating prostate cancer when it’s not necessary exposes men to potential side effects—including incontinence and impotence– of aggressive treatment like surgery. This is known as overtreatment. We need better tools to differentiate aggressive prostate cancer from non-aggressive prostate cancer to guide these decisions.
In 2007, the Canary prostate team decided to focus on this important clinical question. How will we distinguish lethal from non-lethal prostate cancer? Identifying the difference early on will save lives. New tools will also help end unnecessary biopsies and overtreatment.
By 2008, the team launched a clinical trial called PASS, the Prostate Active Surveillance Study. Men with early stage, localized, low-risk prostate cancer can enroll and have their cancer closely monitored for signs of progression. This process is called active surveillance. The trial’s goal is to manage low-risk prostate cancer through active surveillance while identifying markers to distinguish non-aggressive prostate cancer from potentially lethal disease.
The PASS trial has been running smoothly, and in October 2013, the PASS Trial reached another major milestone when the 1,000th man was enrolled in the trial.
We are so grateful for Canary Foundation supporters, who provided funding early on for this work. They recognized that the project was underfunded and important. We’re also extremely thankful to the men who participated in the trial for contributing tens of thousands of samples to prostate cancer early detection research. Thank you!
November 7, 2013
Recently, Canary Foundation and Stanford embarked on a collaboration with the MD Anderson Cancer Center, working together on a large-scale initiative to improve the screening process of lung cancer for earlier detection of this lethal disease.
The Canary lung cancer team leader, Dr. Sam Hanash, was recruited to the MD Anderson Cancer Center, which launched an ambitious Moon Shots Program aimed at rapidly and significantly reducing mortality in several major cancers. Lung cancer is currently the leading cause of cancer deaths.
As part of Moon Shots program, lung cancer physicians and researchers are initiating a screening study to improve screening for lung cancer. The goal is to recruit 10,000 individuals in the U.S., and to partner with international sites, including China and Germany, to conduct studies with an additional 10,000 patients. Canary will be joining forces with MD Anderson, combining CT scan technology and biomarker research to better interpret screening results.
These clinical trials represent the next phase of Canary research, taking the progress we’ve made in the lab and testing it in a larger clinical setting.
October 29, 2013
Photo: The clinical trial coordinators for the Canary Prostate Active Surveillance Study (PASS) accept the 2013 Canary Award on behalf of the Canary Prostate Team.
Dr. Dianne Miller was presented with the award for her team’s success in promoting adoption of ovarian cancer prevention programs throughout the Canadian province of British Columbia. Because lethal ovarian cancer often originates in fallopian tubes, their removal can prevent the development of ovarian cancer, potentially reducing the incidence by 50% or more. Since the advent of the British Columbia educational campaign in September 2010, clinics across the province have seen a practice shift toward removal of fallopian tubes during common gynecological surgeries (such as hysterectomy and tubal ligation), thanks to the efforts of Dr. Miller’s team.
The Canary Prostate team was presented with the Canary Award for the team’s success in meeting or exceeding all of its major milestones in the Prostate Active Surveillance Study (PASS) clinical trial. Earlier in the month of October, 2013, the PASS trial celebrated reaching another major milestone, as the 1,000th participant was enrolled in the trial. The trial’s goal is to manage low-risk prostate cancer through active surveillance while identifying markers to distinguish non-aggressive prostate cancer from potentially lethal disease.
Congratulations to both teams for all their hard work, and to all the Canary teams who work tirelessly to develop research and solutions to make accessible cancer early detection a reality.
October 7, 2013
In the United States, it is estimated that there will be 232,340 new breast cancer cases and 39,620 breast cancer mortalities in 2013. 1 in 8 women will be diagnosed with breast cancer during their lifetime. Despite the widespread use of mammography, the technology is limited as many cancers are missed and conversely many women undergo biopsies and surgeries of benign or non-aggressive tumors.
Canary Foundation is supporting a Breast Cancer Early Detection Initiative focused on finding blood-based and imaging biomarkers to improve the current state of breast cancer early detection. The vision of the blood work is to distinguish women with benign versus malignant tumors, and to identify the aggressive, hard to detect, breast cancers. The vision of the imaging work is to detect breast cancer at the earliest stages, when the tumors are very small.
Canary is committed to funding safe, efficient, cost effective tests for cancer early detection.
October 3, 2013
This past weekend, 800 cyclists converged at VMware village to kick off Canary Challenge 2013, a great increase over the number of riders from last year! Over $800,000 was raised to benefit cancer research at the Stanford Cancer Institute and Canary Center for Cancer Early Detection at Stanford.
There were a total of 78 teams participating, with over 120 volunteers cheering, manning registration, and passing out drinks and snacks to replenish riders along the route. Most incredible was the great energy at the event – participants’ dedication and commitment to the cause was palpable, and the celebratory air when cyclists returned triumphant from their rides was electric.
We loved when riders stopped by the social photo booth to show us “#WhyIRideCanary”. Everyone who contributed to the event did so because they were inspired by the need for cancer early detection research. It was incredible to hear their stories – a great reminder of why we ride.
A great thank you to all the riders, sponsors, volunteers and staff who came together on September 28 to make this ride such a great success. Ride on, Canary Challenge participants! Save the date for next year: September 27, 2014!
September 18, 2013
We’re currently 10 days away from the Canary Challenge, and weather reports show that conditions will be perfect the day of the ride. We are so excited to see all the riders, sponsors, and volunteers (and their families) at the Canary Challenge on the 28th!
Currently, we’re running a contest to get you excited about raising funds for cancer early detection and getting your friends signed up for the ride. The incentive? A pair of FABULOUS high end display goggles from Recon Instruments (UVEX Model G.GL9). These goggles give you all the information you could ever dream of wanting delivered instantly, hands free and direct to eye. It’s the world’s first heads up display for sports. Thanks to Recon Instruments for their generous donation!
This incredible prize will go to the first three cyclists who complete two tasks:
1: Raise at least $400 or more
2: Bring in ONE new cyclist who raises $400 or more
The deadline for this contest is Monday, September 23. To participate, complete the steps above and email Jesse to let him know you’re eligible for the prize.
Additionally, we’d like to call attention to the top five Canary Challenge fundraisers so far. These individuals have collectively raised more than $45,000 and they’re still going strong!
- Julie Kaufman ($11,667.00)
- Steve Ciesinski ($10,695.00)
- Don Listwin ($10,000.00)
- Stephen Rooks ($8,000.00)
- Patrick Gelsinger ($6,850.00)
Many thanks to these fundraisers for serving as such great inspiration to keep reaching for as many donations as possible to benefit cancer early detection research at the Stanford Cancer Institute and the Canary Center at Stanford. Way to go!